Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 31;13(10):2466-2478.
doi: 10.21037/tlcr-24-425. Epub 2024 Oct 28.

Systems mapping: a novel approach to national lung cancer screening implementation in Australia

Affiliations
Review

Systems mapping: a novel approach to national lung cancer screening implementation in Australia

Sandra Marjanovic et al. Transl Lung Cancer Res. .

Abstract

Background: Lung cancer screening with low-dose computed tomography has been started in some high-income countries and is being considered in others. In many settings uptake remains low. Optimal strategies to increase uptake, including for high-risk subgroups, have not been elucidated. This study used a system dynamics approach based on expert consensus to identify (I) the likely determinants of screening uptake and (II) interactions between these determinants that may affect screening uptake.

Methods: Consensus data on key factors influencing screening uptake were developed from existing literature and through two stakeholder workshops involving clinical and consumer experts. These factors were used to develop a causal loop diagram (CLD) of lung cancer screening uptake.

Results: The CLD comprised three main perspectives of importance for a lung cancer screening program: participant, primary care, and health system. Eight key drivers in the system were identified within these perspectives that will likely influence screening uptake: (I) patient stigma; (II) patient fear of having lung cancer; (III) patient health literacy; (IV) patient waiting time for a scan appointment; (V) general practitioner (GP) capacity; (VI) GP clarity on next steps after an abnormal computed tomography (CT); (VII) specialist capacity to accept referrals and undertake evaluation; and (VIII) healthcare capacity for scanning and reporting. Five key system leverage points to optimise screening uptake were also identified: (I) patient stigma influencing willingness to receive a scan; (II) GP capacity for referral to scans; (III) GP capacity to increase patients' health literacy; (IV) specialist capacity to connect patients with timely treatment; and (V) healthcare capacity to reduce scanning waiting times.

Conclusions: This novel approach to investigation of lung cancer screening implementation, based on Australian expert stakeholder consensus, provides a system-wide view of critical factors that may either limit or promote screening uptake.

Keywords: Delivery of Health Care; Lung neoplasms; mass screening; system dynamics.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-425/coif). E.S. received speaker honoraria from Astra Zeneca, Merck Sharp & Dohme and the Limbic; support for attending meetings and travel from Astra Zeneca LOBES 2022; received ad hoc advisory board payment from Bristol Myers Squibb 2022. E.S. is the Deputy Board Chair Thoracic Oncology Group of Australasia (unpaid) and also the Editor-in-chief for the JTO CRR. F.B. reports honoraria for educational talks to primary care and secondary care specialists from Boehringer Ingelheim and Astra Zeneca. N.N. reports research funding from a Medical Research Council Clinical Academic Research Partnership, CRUK, NIHR, Horizon Europe and UKRI (Grant number MR/T02481X/1); reports honoraria for non-promotional educational talks or advisory boards from Astra Zeneca, Bristol Myers Squibb, Fujifilm, Intuitive, Janssen, Lilly, Merck Sharp & Dohme, Olympus, Sanofi and Roche; he also received support for attending meetings from Astra Zeneca, Fujifilm, Intuitive, Merck Sharp & Dohme and Olympus. He also reports consulting fees from Amgen, Astra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, EQRx, Fujifilm, Guardant Health, Intuitive, Janssen, Lilly, Merck Sharp & Dohme, Olympus, and Roche and has leadership roles for the British Thoracic Oncology Group, UK Lung Cancer Coalition and National Lung Cancer Audit. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Reinforcing (positive) and balancing (negative) feedback loops. ‘S’ = relationship between two variables change in the same direction. ‘O’ = variables change in the opposite direction (i.e., an increase in one variable causes a decrease in the connected variable).
Figure 2
Figure 2
Flowchart for methodological steps. CLD, causal loop diagram.
Figure 3
Figure 3
Causal loop diagram of lung cancer screening in Australia. LC, lung cancer; GP, general practitioner; CT, computed tomography; IT, information technology; Specialist capacity w/expertise, specialist capacity with expertise.

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49. 10.3322/caac.21660 - DOI - PubMed
    1. Australian Institute of Health and Welfare. Cancer in Australia 2021. Canberra (AU): Australian Government, Department of Health and Aged Care; 2021 [cited 2023 Oct 20]. Available online: https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2021/summary
    1. Cancer Australia. National Cancer Control Indicators. Relative survival by stage at diagnosis (lung cancer) 2019. Canberra (AU): Australian Government, Department of Health and Aged Care; 2019 [cited 2023 Oct 10]. Available online: https://ncci.canceraustralia.gov.au/outcomes/relative-survival-rate/rela...
    1. Cancer Australia. National Cancer Control Indicators. Cancer incidence (lung cancer) 2019. Canberra (AU): Australian Government, Department of Health and Aged Care; 2019 [cited 2024 July 5]. Available online: https://ncci.canceraustralia.gov.au/diagnosis/cancer-incidence/cancer-in...
    1. Zhang Y, Simoff MJ, Ost D, et al. Understanding the patient journey to diagnosis of lung cancer. BMC Cancer 2021;21:402. 10.1186/s12885-021-08067-1 - DOI - PMC - PubMed